
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay Ltd has experienced a favorable increase in its equipment utilization rate by over 50% following strategic investments, highlighting the operational efficiency of its Deep Transcranial Magnetic Stimulation (Deep TMS) platform. As the company moves towards a pay-per-use model and benefits from an expanding prescriber base, particularly among neurologists, there is strong potential for accelerated revenue growth in the coming years. Additionally, the company's clinic infrastructure is being increasingly optimized to offer complementary treatments, positioning BrainsWay favorably within the evolving mental health treatment landscape.
Bears say
BrainsWay Ltd faces several significant risks that contribute to a negative outlook on its stock performance. Key concerns include the slower-than-expected adoption of its Deep TMS systems, alongside challenges in expanding reimbursements and market access, which are critical for revenue generation. Additionally, the company's difficulties in advancing other clinical indications and the potential for long-term dilution further exacerbate the financial uncertainties surrounding its operations.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares